SAN FRANCISCO and SUZHOU, China, June 22, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced that multiple exploratory mechanism-of-action (MoA) analyses of mazdutide (investigator-initiated trials) as well as a preclinical study of IBI3030 (PCSK9-GGG antibody-peptide-conjugate) will be showcased at the American Diabetes Association's (ADA) 85th Scientific Sessions. Details are listed below：

Title: A novel antibody-peptide conjugate targeting PCSK9, GLP-1R, GCGR, GIPR improves cardiovascular risk markers in preclinical study
Abstract Number：1886-LB
Presentation Form: Poster
Presentation Time: Sunday, June 22, 2025. 12:30 P.M. - 1:30 P.M. CDT
Location: Poster Hall (Hall F1)
Author: Dr. Decheng Ren, Innovent Biologics

IBI3030 is a novel anti-PCSK9 antibody conjugated with peptides targeting GLP-1R, GCGR, and GIPR. Through multi-target synergistic effects, it significantly improves cardiovascular metabolic risk indicators. Mechanistically, the anti-PCSK9 antibody component inhibits LDL receptor degradation, thereby lowering reduce plasma LDL-c levels. Simultaneously, the triple-target agonist peptide activates GLP-1R/GCGR/GIPR receptors, enhancing hepatic fatty acid oxidation capacity, with demonstrates superior efficacy compared to the control. Preclinical studies demonstrate that in multiple models (mice, rats, and non-human primates), IBI3030 significantly reduces LDL-c (p<0.01 vs. baseline) and Lp(a), improves oral glucose tolerance (OGTT) (effective even in GLP-1R knockout mice), reduces body weight, and preserves insulin sensitivity. Additionally, it exhibits excellent safety in non-human primates, with a maximum tolerated dose reaching 50 mg/kg.

Furthermore, mazdutide, the fastest-developing dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist globally, has ignited significant research interest in the scientific community due to its comprehensive metabolic benefits. This year's ADA Annual Meeting featured multiple MoA studies on mazdutide's effects in reducing liver fat, improving fibrosis, and lowering serum uric acid. The following are investigator-initiated studies:

Topic: The Dual Glucagon and Glucagon-Like Peptide 1 Receptor Agonist Mazdutide Outbalanced Glucagon-Like Peptide 1 Receptor Agonist Semaglutide Monotherapy in Improving Mice Liver Fat Accumulation
Abstract Number: 777-P
Presentation Form: Poster
Presentation Time: Sunday, June 22, 2025. 12:30 P.M. - 1:30 P.M. CDT
Location: Poster Hall (Hall F1)
Author: Tianpei Hong, Peking University Third Hospital

Liver RNA-sequencing and KEGG enrichment analysis showed that compared with Semaglutide treatment, Mazdutide treatment predominantly activated oxidative phosphorylation and fatty acid degradation pathways. Meanwhile, lipid metabolism-related genes were upregulated in Mazdutide group compared to Semaglutide group. We further screened differentially expressed transcription factors (TF) through the TRRUST database and found that activating transcription factor 3 (Atf3) upregulated in the Mazdutide treatment group might be the functional TF regulating lipid degradation in the liver. The dual GCGR/GLP-1R agonist mazdutide exhibited a better efficacy in weight loss and liver fat accumulation alleviation compared with the GLP-1R agonist semaglutide monotherapy potentially due to its promotion of fatty acid oxidation via transcription factor ATF3.

Topic: Mazdutide，a GCG/GLP-1R dual-agonist, alleviates MASH and hepatic fibrosis
Abstract Number: 1616-P
Presentation Form：Poster
Presentation Time: Sunday, June 22, 2025. 12:30 P.M. - 1:30 P.M. CDT
Location: Poster Hall (Hall F1)
Author: Ling Li, Zhongda Hospital, School of Medicine, Southeast University,

With the mice presented NASH and fibrosis phenotypes, Mazdutide decreased body weight, liver weight and hepatic triglyceride levels. Notably, Mazdutide also mitigated hepatic fat accumulation, inflammation, and hepatic fibrosis, compared with a single GLP1R or GCGR agonist. Therefore, Mazdutide alleviates hepatic fibrosis in MASH mice and regulates lipid metabolism as well as the gut microbiota, which may contribute to providing a novel therapeutic method and therapeutic target for MASH

Topic: Mazdutide, a Dual GLP-1R/GCGR Agonist, Alleviates Hyperuricemia by Modulating Hepatic Energy and Lipid Metabolism and Inhibiting Purine Pathways
Abstract Number: 775-P
Presentation Form: Poster
Presentation Time: Sunday, June 22, 2025. 12:30 P.M.- 1:30 P.M. CDT
Location: Poster Hall (Hall F1)
Author: Hongwei Jiang, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology

Mazdutide significantly lowers serum uric acid levels in hyperuricemic rats, primarily by enhancing fatty acid oxidation and regulating cellular energy metabolism within hepatocytes. This process suppresses the expression of genes associated with glucose and purine metabolism in the liver, leading to a reduction in the generation and utilization of purine precursors. SnRNA-Seq analysis indicates that mazdutide increases the expression of GCGR in hepatocytes, whereas semaglutide slightly inhibits it. In hyperuricemic rats, the expression of key genes involved in fatty acid oxidation, such as Cpt1a, Fabp1, Apoa1, Acox1, and Acaa1a is significantly reduced. However following Mazdutide treatment, the expression of these genes markedly increases, promoting fatty acid oxidation and improving overall energy metabolism. In contrast, genes associated with fatty acid synthesis, such as Acaca and Fasn, show a significant reduction in expression. Furthermore, after Mazdutide intervention, the expression of genes related to glucose metabolism and purine metabolism, including Pklr, G6pc1, Glul, Gckr, Gk, Nt5e, and Ppat, also experience significant decreases. This shift may reflect a change in cellular metabolism towards more efficient fatty acid oxidation, resulting in reduced the generation and utilization of purine precursors. Compared to Semaglutide, Mazdutide offers more substantial benefits in lowering uric acid levels.

Dr. Lei Qian from Innovent Biologics, stated, "We are delighted to see mazdutide's mechanism exploration studies featured extensively at the ADA conference. The growing body of scientific evidence will further validate mazdutide's differentiated profile as a next-generation GCG/GLP-1 dual receptor agonist, particularly in liver fat and serum urine reduction. Moreover, in the field of cardiovascular and metabolic diseases, Innovent is dedicated to developing next-generation innovative therapies. This includes IBI3030 (PCSK9-GGG), a novel modality with a unique MoA that embodies an innovative 'one-drug, multiple-effects' therapeutic strategy. IBI3030 has the potential to deliver comprehensive therapeutic benefits and meaningfully improve outcomes for more patients worldwide."

*Poster 2-4 are results from investigator-initiated trials (IITs)

About Mazdutide (IBI362)

Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of mazdutide, a GLP-1R and GCGR dual agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, mazdutide may offer additional benefits beyond those of GLP-1 receptor agonists—such as promoting insulin secretion, lowering blood glucose and reducing body weight—by also activating the glucagon receptor to increase energy expenditure and improve hepatic fat metabolism. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies. It has also shown benefits in reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes, and liver fat content, as well as improving insulin sensitivity.

Currently, Mazdutide has two NDAs accepted for review by NMPA, including for:

• Long-term weight management in adults with obesity or overweight.
• Glycemic control in adults with type 2 diabetes (T2D).

Mazdutide is currently being evaluated in seven Phase 3 clinical studies, including:

• GLORY-1: A Phase 3 trial in Chinese participants with overweight or obesity.
• GLORY-2: A Phase 3 trial in Chinese participants with moderate-to-severe obesity.
• GLORY-3: A Phase 3 trial comparing mazdutide and semaglutide in Chinese participants with overweight/obesity and metabolic dysfunction-associated fatty liver disease (MAFLD).
• GLORY-OSA: A Phase 3 trial in Chinese participants with obstructive sleep apnea (OSA) and obesity.
• DREAMS-1: A Phase 3 trial in treatment-naïve Chinese participants with T2D.
• DREAMS-2: A Phase 3 trial comparing mazdutide and dulaglutide in Chinese T2D participants with inadequate glycemic control on oral antidiabetic drugs.
• DREAMS-3: A Phase 3 trial comparing mazdutide and semaglutide in Chinese participants with T2D and obesity.

Among these, GLORY-1, DREAMS-1, and DREAMS-2 have already met their primary endpoints and the other four studies are currently ongoing.

In addition, several new clinical studies of mazdutide are initiated or planned, including:

• A Phase 3 trial in adolescents with obesity.
• New studies in metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF).

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched [15/16] products in the market. It has [3/2] new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s).

Forward-looking statement

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.

The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.

GUANGZHOU, China, June 20, 2025 /PRNewswire/ -- MINISO Group Holding Limited (NYSE: MNSO; HKEX: 9896) ("MINISO", "MINISO Group" or the "Company"), a global value retailer offering a variety of trendy lifestyle products featuring IP design, today announced that it has been informed by Mr. Guofu Ye, the chairman of the board of directors, the chief executive officer and the controlling shareholder of the Company, of the full unwinding of his personal collar transaction with a leading financial institution (the "Dealer").

Under the terms of the unwinding, the Dealer has returned all 14,000,000 ordinary shares of the Company (the "Shares") that were previously transferred to it as credit support in connection with a prepaid forward contract (the "Contract") for this collar transaction. This Contract was entered into in 2023 between the Dealer and Mini Investments SP1 Limited ("Mini Investments"), a BVI entity controlled by Mr. Ye. As part of the Contract, Mini Investments transferred 14,000,000 Shares to the Dealer in return for a prepayment from the Dealer, while agreeing to settle the Contract at expiration with either a cash payment or delivery of the shares. With the unwinding of the transaction, the Company understands that Mini Investments has received back all 14,000,000 Shares.

The Company believes that Mr. Ye's decision to unwind the collar transaction and regain these MINISO shares demonstrates his continued confidence in and commitment to the long-term success of the Company.

About MINISO Group

MINISO Group is a global value retailer offering a variety of trendy lifestyle products featuring IP design. The Company serves consumers primarily through its large network of MINISO stores, and promotes a relaxing, treasure-hunting and engaging shopping experience full of delightful surprises that appeals to all demographics. Aesthetically pleasing design, quality and affordability are at the core of every product in MINISO's wide product portfolio, and the Company continually and frequently rolls out products with these qualities. Since the opening of its first store in China in 2013, the Company has built its flagship brand "MINISO" as a globally recognized retail brand and established a massive store network worldwide. For more information, please visit https://ir.miniso.com/.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "anticipate", "aim", "estimate", "intend", "plan", "believe", "is/are likely to", "potential", "continue" or other similar expressions. Among other things, the quotations from management in this announcement, as well as MINISO's strategic and operational plans, contain forward-looking statements. MINISO may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC") and The Stock Exchange of Hong Kong Limited (the "HKEX"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about MINISO's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: MINISO's mission, goals and strategies; future business development, financial conditions and results of operations; the expected growth of the retail market and the market of branded variety retail of lifestyle products in China and globally; expectations regarding demand for and market acceptance of MINISO's products; expectations regarding MINISO's relationships with consumers, suppliers, MINISO Retail Partners, local distributors, and other business partners; competition in the industry; proposed use of proceeds; and relevant government policies and regulations relating to MINISO's business and the industry. Further information regarding these and other risks is included in MINISO's filings with the SEC and the HKEX. All information provided in this press release and in the attachments is as of the date of this press release, and MINISO undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Investor Relations Contacts: 

MINISO Group Holding Limited
Email: [email protected]
Phone: +86 (20) 36228788 Ext.8039

• China Mobile and ZTE have developed the innovative AI-driven green and energy-saving 5G cloudified core network project to reduce the energy consumption and improve the network performance and operation efficiency
  
  
• The AI-driven green and energy-saving 5G cloudified core network innovative and replicable solution helps operators reduce OPEX and CAPEX while achieving significant energy saving effect

SHANGHAI, June 20, 2025 /PRNewswire/ -- ZTE Corporation (0763.HK / 000063.SZ), a global leading provider of integrated information and communication technology solutions, in partnership with China Mobile, has earned "Best Mobile Innovation for Climate Action in Asia" award for their AI-driven green and energy-saving 5G cloudified core network innovation project at the Asia Mobile Awards(AMOs) during MWC Shanghai 2025.

Energy conservation, emission reduction and green transformation in the communications industry are key issues in the global shift towards green and sustainable development.

The innovative AI-driven green and energy-saving 5G cloudified core network project aims to significantly reduce the energy consumption of the 5G core network while enhancing network performance and operation efficiency through the innovative cloud-native architecture and intelligent energy-saving technology. Leveraging ZTE's leading Intelligent 5G core network solutions and China Mobile's extensive experience in green communications, this project successfully achieves energy efficiency optimization and carbon emission reduction of 5G core network, providing operators with efficient and environmentally-friendly 5G core network deployment solutions.  

The AI-driven green and energy-saving 5G cloudified core network innovation project not only helps operators reduce OPEX and CAPEX, but also provides replicable solutions for the sustainable development of global 5G core networks. To date, this project has been deployed across multiple provinces of China, achieving significant energy savings.

Moving forward, ZTE will further its collaboration with China Mobile to promote the application of green and energy-saving technologies in a wider range of network systems. Both parties will work together with global partners to advance the green and intelligent development of 5G networks, with great commitment to the sustainable development of the global communications industry.

ABOUT ZTE:
ZTE connects the world with continuous innovation for a better future. The company provides innovative technologies and integrated solutions, and its portfolio spans communication networks, computing infrastructure, industry digital solutions, and personal and home smart terminals. Serving over a quarter of the world's population, ZTE is dedicated to leading globally in connectivity and intelligent computing, enabling communication and trust everywhere. ZTE is listed on both the Hong Kong and Shenzhen Stock Exchanges.
www.zte.com.cn/global

FOLLOW US:
Facebook www.facebook.com/ZTECorp
X www.x.com/ZTEPress
LinkedIn www.linkedin.com/company/zte
YouTube www.youtube.com/@ZTECorporation

MEDIA INQUIRIES:
ZTE Corporation
Communications
Email: [email protected]

上海 2025年6月20日 /美通社/ -- 近日，2025年亞洲移動大獎（AMO大獎）出爐，中國移動與中興通訊合作的基於AI驅動的綠色節能5G 雲化核心網創新項目，榮獲GSMA 「亞洲最佳氣候行動移動創新獎」。

在全球積極倡導綠色可持續發展的時代背景下，通信行業的節能減排與綠色轉型成為了關鍵議題。AI驅動的綠色節能5G 雲化核心網創新項目，旨在通過創新的雲原生架構和智能化節能技術，顯著降低5G核心網的能耗，同時提升網絡性能和運營效率。該項目基於中興通訊領先的智能化5G核心網解決方案，結合中國移動在綠色通信領域的豐富實踐經驗，成功實現了5G核心網網絡的能效優化和碳排放減少，為運營商提供了高效、環保的5G網絡部署方案。

綠色節能5G 雲化核心網創新項目不僅可幫助運營商降低運營成本（OPEX）和資本支出（CAPEX），還可為全球5G網絡的可持續發展提供了可複製的解決方案。

目前，該項目已在中國移動的多個省市進行試點部署，並取得了顯著的節能效果。

未來，中興通訊將繼續攜手中國移動，推動綠色節能技術在更大範圍和更多網絡系統的落地應用。雙方將攜手全球合作夥伴，共同推動5G網絡的綠色化、智能化發展，為全球通信行業的可持續發展貢獻力量。

Email:
[email protected]

Amazon (AMZN.US)'s AWS held the Amazon Cloud Technology China Summit, during which it announced that GWMOTOR (02333.HK) has built a global contact center by leveraging AWS' omnichannel solution, Amazon Connect, which can enable end-to-end optimization of global customer service from unified channels and graded customer complaint handling and follow-up, to closed-loop management and performance assessment.

This system is already in use in the Netherlands and is planned for phased rollout in eight countries worldwide, with the goal of greatly enhancing GWMOTOR's overseas after-sales service quality and customer satisfaction.
~



AAStocks Financial News
Web Site: www.aastocks.com

The First Department of Equipment Industry of the Ministry of Industry and Information Technology, the Quality Development Bureau of the State Administration for Market Regulation (SAMR), and the Fire Supervision Department of the National Fire and Rescue Administration jointly held a video conference to strengthen the safety management of new energy vehicles (NEVs).

The meeting required vehicle manufacturers and power battery producers to focus on risk prevention throughout product design verification, manufacturing, and after-sales service, and strictly prohibit exaggerated or false advertising.

At the same time, companies must avoid "involutionary" competition, and must never cut corners or use inferior materials, nor should they sacrifice product performance or lower product quality for the sake of short-term cost reduction and efficiency gains.
~



AAStocks Financial News
Web Site: www.aastocks.com

SHANGHAI, June 19, 2025 /PRNewswire/ -- ZTE Corporation (0763.HK / 000063.SZ), a global leading provider of integrated information and communication technology solutions, announced that Cui Li, the company's Chief Development Officer (CDO), was invited to deliver a keynote speech at "The Techco Transformation: Pioneering the Next Era of Innovation" session and addressed the GTI Summit • Shanghai 2025 with the theme of "Envisioning the Future From 5G-A to 6G" at MWC25 Shanghai. She shared ZTE's innovative practices and strategic insights on driving the digital and intelligent evolution of diverse industries amidst the intelligent revolution powered by AI large models.

In her keynote speech at the "The Techco Transformation: Pioneering the Next Era of Innovation" session, Cui Li shared her insights under the theme "Digital and Intelligent Evolution: Usher in a New Era of AI Civilization". She underscored that large AI models have triggered a global wave of intelligent revolution, driving continuous innovations and breakthroughs across technological iterations and ecosystem development. Emphasizing the enduring priorities within AI advancement, she asserted that the focus will remain unwavering: efficient infrastructure, optimized algorithms, and practical applications. In alignment with this trajectory, ZTE prioritizes computing infrastructure, algorithm optimization, and edge-terminal collaboration. Through relentless innovation, ZTE is committed to advancing the democratization of computing and AI, laying a solid foundation for the intelligent transformation of various industries.

Driven by innovation, ZTE strives to build an intelligent foundation integrating "network, computing, and energy". Centered on data, algorithms, and technology, the company pursues multidimensional evolution to unleash greater intelligent value. Adhering to the core philosophy of "AI for All", ZTE integrates AI deeply with ICT to build a full-stack and full-scenario intelligent computing solution. Additionally, the company is actively driving the adoption of AI across consumer, home, and industry scenarios, accelerating AI democratization. Cui Li stated that ZTE will continue to enhance the competitiveness of its products and solutions, build a more integrated ecosystem with the its partners, and foster deeper convergence and innovation of AI and ICT. Together with ecosystem partners, ZTE aims to address the challenges of privacy, security, and ethics in AI, so as to create an open, collaborative, and trustworthy ecosystem and promote digital and intelligent advancements across all industries, opening up a new era of civilization.

At the GTI Summit • Shanghai 2025, Cui Li delivered a speech titled "Intelligent Connectivity, Infinite Future", and was invited to the official release ceremony of China Mobile 5G-A Enablement for the Trifecta of New Information Consumption Services White Paper and other innovation initiatives. In her speech, Cui Li shared ZTE's systematic exploration, practical achievements, and strategic insights across three dimensions: advanced connectivity, intelligent computing for all, and deployment on edges and terminals.

In terms of advanced connectivity, ZTE collaborates with partners to drive network technology evolution from 5G to 5G-A and eventually to 6G, building the neural hub for the intelligent era. Regarding intelligent computing, ZTE focuses on hardware, software, and data to build efficient infrastructure, enable effective implementation, and enhance intelligence. As a result, the company maximizes the value of data, and significantly advances AI for all. As for deployment on edges and terminals, adhering to the "AI for All" philosophy, ZTE has launched a full-stack, full-scenario intelligent solution, contributing to reduced costs, higher efficiency, and lower carbon emissions of the entire society. In her speech, Cui Li emphasized that the world of intelligent connectivity is not a solo of technology, but a symphony played by the entire ecosystem. ZTE will join hands with global partners to further democratize AI and other new technologies, and empower the digital and intelligent transformation of various industries, ultimately shaping a future with ubiquitous connectivity, boundless intelligence, and infinite possibilities.

For Cui Li's keynote speech titled "Digital and Intelligent Evolution: Usher in a New Era of AI Civilization", please visit:

https://www.zte.com.cn/global/about/news/zte-cdo-cui-li-at-mwc25-shanghai-digital-and-intelligent-evolution-usher-in-a-new-era-of-ai-civilization.html

Media Inquiry:
Email: [email protected]

As the price war among Chinese carmakers continues, Bloomberg quoted statistics from the Shanghai-based Gasgoo Research Institute as saying that China's annual auto output was as high as 55.5 million vehicles, but 2024 capacity utilization rate was only 49.5%, meaning more than half of output in China's auto industry are still idle.

Haima Automobile, which was originally invested by FAW JIEFANG(000800.SZ) and set up as a joint venture with Japan's Mazda Motor (7261.JP) in the early years of the company's history, had a capacity utilization rate of only 1.5% last year, according to data.

On the other side of the market, leading companies had significantly higher capacity utilization rates, the report added. BYD COMPANY (01211.HK)'s 2024 capacity utilization rate was 82.1%, and continued to expand domestic and overseas factories, becoming one of the most aggressive carmakers in the current price war.

Furthermore, some of the leading competitive companies are operating at nearly full capacity, thanks to strong domestic demand and large export scale, with Tesla (TSLA.US)'s Shanghai factory reaching a 96.1% capacity utilization rate last year.
~



AAStocks Financial News
Website: www.aastocks.com

上海 2025年6月19日 /美通社/ -- 6月18日，2025 MWC上海正式啟幕，中興通訊首席發展官崔麗應邀出席在同日舉行的「科技企業轉型：引領創新新時代」主旨演講和以「預見未來，從5G-A到6G」為主題的2025 GTI上海國際產業大會，分享中興通訊在AI大模型驅動的智能革命浪潮中，推動千行百業數智進階的創新實踐和戰略思考。

在「科技企業轉型：引領創新新時代」主旨演講中，崔麗以《數智進階，開啟文明新徵程》為主題展開分享。她指出， AI大模型在全球掀起智能革命浪潮，經歷了從技術迭代到生態共生的「光速」發展，無論未來AI技術發展的方向和節奏如何變化，高效基礎設施、高效算法以及應用落地依然是主旋律，中興通訊主張發力「算力築基、算法提效、邊端協同」，通過融合創新持續推動數智進階、算力普惠與AI平權，為千行百業智能革命構築堅實基礎：以創新為引擎，全力打造「網絡、算力、能源」三位一體的智能基座；圍繞數據、算法和技術融合，多維進化提升智能效益；以「AI for All」為核心理念，將AI與ICT技術及產品深度融合，構建全棧式智能解決方案，並積極在消費者、家庭和行業場景推動AI落地實踐，加速智能普及。崔麗表示，中興通訊將持續提升產品方案競爭力、生態整合力和夥伴賦能體系，深化AI與ICT技術融合創新，攜手生態夥伴在AI的隱私、安全、倫理等挑戰上持續努力，加速打造開放協作可信的繁榮生態，推動千行百業數智進階，開啟文明新徵程。

在 2025 GTI上海國際產業大會，崔麗以《智聯無界，共築未來》為題發表演講，並受邀參加中國移動《5G-A賦能信息消費新三樣業務白皮書》等相關創新成果發佈儀式。在演講中，崔麗分享了中興通訊圍繞連接技術升級、智能算力普惠、邊端協同佈局三大維度展開的系統性探索實踐成果與戰略思考。連接升級方面，中興通訊攜手合作夥伴從5G到5G-A，再到6G持續引領網絡技術升級，為智能時代構築神經中樞；智能算力方面，通過高效基座、高效落地、高效增智三大主張，硬件、軟件、數據三管齊下，實現數據價值的深度挖掘釋放，協同推動智能開放普惠；邊端佈局方面，以「AI for All」為核心理念，構建全棧式智能解決方案，為社會運行體系向降本增效和低碳方向發展貢獻自身力量。她強調，智聯世界不是單點技術的狂歡，而是生態共榮的協奏曲，中興通訊將與全球夥伴攜手，推動人工智能等新技術進一步開放普惠，助力千行百業數智化轉型升級，共築一個無界連接、無限智能、無盡可能的未來。

瞭解中興通訊首席發展官崔麗《數智進階，開啟文明新徵程》主旨演講全文，請查閱：

https://www.zte.com.cn/china/about/news/20250618c10.html

媒體垂詢：

Email: [email protected]

Li Xiang, Chairman and CEO of LI AUTO-W (02015.HK), revealed that the company has already built 2,500 5C supercharging stations so far, meaning that the number of LI AUTO-W's supercharging stations has surpassed Tesla (TSLA.US) in the Chinese market.

LI AUTO-W has been the fastest car company in building charging stations over the past two years as it aims to continuously create a driving environment without range anxiety for its electric vehicle users, Li explained. The company will continue to construct more and better supercharging stations on highways and across cities for its customers.
~



AAStocks Financial News
Web Site: www.aastocks.com